| Literature DB >> 35216193 |
Ping Li1, Wenli Lan1, Jiaying Li1, Yanping Zhang1, Qiuhong Xiong1, Jinpei Ye1, Changxin Wu1, Han Xiao1.
Abstract
Small patella syndrome (SPS) is a rare autosomal dominant disorder caused by mutations in TBX4 gene which encodes a transcription factor of FGF10. However, how TBX4 mutations result in SPS is poorly understood. Here, a novel TBX4 mutation c.1241C>T (p.P414L) was identified in a SPS family and series of studies were performed to evaluate the influences of TBX4 mutations (including c.1241C>T and two known mutations c.256G>C and c.743G>T). Results showed that mesenchymal stem cells (MSCs) with stable overexpression of either TBX4 wild-type (TBX4wt) or mutants (TBX4mt) were successfully generated. Immunofluorescence study revealed that both the overexpressed TBX4 wild-type and mutants were evenly expressed in the nucleus suggesting that these mutations do not alter the translocation of TBX4 into the nucleus. Interestingly, MSCs overexpression of TBX4mt exhibited reduced differentiation activities and decreased FGF10 expression. Chromatin immunoprecipitation (ChIP) study demonstrated that TBX4 mutants still could bind to the promoter of FGF10. However, dual luciferase reporter assay clarified that the binding efficiencies of TBX4 mutants to FGF10 promoter were reduced. Taken together, MSCs were firstly used to study the function of TBX4 mutations in this study and the results indicate that the reduced binding efficiencies of TBX4 mutants (TBX4mt) to the promoter of FGF10 result in the abnormal biological processes which provide important information for the pathogenesis of SPS.Entities:
Keywords: FGF10; TBX4 mutation; mesenchymal stem cell; small patella syndrome
Mesh:
Substances:
Year: 2022 PMID: 35216193 PMCID: PMC8875086 DOI: 10.3390/ijms23042075
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Analysis of a novel TBX4 mutation. (A) The pedigree of the family with three patients and the proband is indicated by arrow. (B) Leg appearance photo of the proband I-2. (C) X-ray report of the proband I-2. (D) Sanger sequencing results from the three patients and a healthy control, the mutation sites are indicated by arrows.
Figure 2Generation of mesenchymal stem cells (MSCs) cell lines with stable overexpression of either TBX4wt or TBX4mt. (A) Schematic of the secondary structure and functional domains of the TBX4 protein. The distribution of three mutations in TBX4 are indicated by arrow. The T-box domain, nuclear localization signal and regulatory interaction domain are shown in yellow, green and blue, respectively. (B) Conservation of the 414th amino acid in TBX4 protein among different species. NCBI accession numbers are: Homo sapiens: NP_001308049.1; Callithrix jacchus: XP_035156592.1; Cervus canadensis: XP_043337426.1; Mesocricetus auratus: XP_040605335.1; Mus musculus: NP_035666.2; Rattus norvegicus: NP_001100504.1. (C) Brightfield and immunofluorescence images of the overexpressed GFP fusion proteins in MSCs. Bar: 200 mm. (D) Western blot analysis for stable overexpression MSCs lysates. The molecular weights of expected band are 87 KDa with TBX4 (60 KDa) and GFP (27 KDa) in total.
Figure 3Analysis of TBX4 mutations. (A) Localization of TBX4wt or TBX4mt GFP fusions in HeLa cells, and GFP was used as control. Bar: 25 μm. (B) Osteogenic differentiation of mesenchymal stem cells (MSCs) overexpression of either TBX4wt or TBX4mt. The number of red calcium nodules correlates with the degree of cell differentiation. Bar: 200 mm. (C) Visualization of senescence associated β-galactosidase staining between wild-type and mutant TBX4 transfected cells. X-Gal was used as a substrate for β-galactosidase, and dark blue products inside cells were produced when catalyzed by aging-specific β-galactosidase. Examination for staining was performed after overnight incubation under bright field microscopy at 200× magnification. Bar: 200 mm. (D) Statistics of senescence associated β-galactosidase assay. The blue cells were counted, and the percentages of blue cells in total were calculated. SPSS was applied for statistics analysis (** p < 0.01).
Figure 4Investigations on TBX4-FGF10 pathway. (A) Quantification of the relative expression of FGF10 mRNA in mesenchymal stem cells (MSCs) with stable overexpression of either TBX4wt or TBX4mt using qRT-PCR. Data represent the mean ± SD of three independent experiments performed in triplicate. (B) Chromatin immunoprecipitation (ChIP) assay for MSCs with overexpression of either TBX4wt or TBX4mt. (C) The FGF10 promoter with 3.7 kb was amplified by PCR. (D) Relative luciferase activities in cells co-transfected pGL3-FGF10 with TBX4 wild type or mutants, respectively (* p < 0.05; ** p < 0.01).
Figure 5Schematic diagram of TBX4 mutations resulting in small patella syndrome (SPS). Arrows indicate that TBX4 mutations do not alter the translocation of TBX4 into the nucleus. The dashed oval indicates the reduced binding efficiency of TBX4 mutants with the FGF10 promoter.